Ingen Technologies, Inc. of the US has announced that it is responding to current statistics concerning chronic obstructive pulmonary disease (COPD), with the launch of its new Oxyview respiratory product.
COPD affects one in every four men and one in every six women who reach the age of 95.
Associated with Cardiovascular disease, diabetes and hypertention, COPD is reckoned to be the third leading cause of death globally. A recent report approximates that there are 32 million diagnosed COPD victims in the US alone, the majority of which require oxygen therapy.
Oxyview is thought to be the world’s first Patient In-Line Oxygen Flow-Meter, manufactured in the US by Ingen Technologies and providing more confidence and assurance to patients using oxygen.
Reusable and requiring no batteries, the new device works in any position with all liquid or gas O2 systems.
Dr. Vlady Rozenbaum, leading scientist and Board Member of several COPD organisations gave the following statement, “Truly a great idea. I have already started demonstrating the Oxyview to patients and medical professionals.”